Zelenectide Pevedotin Research for Metastatic Urothelial Carcinoma
An evidence-based overview of research examining Zelenectide Pevedotin in the context of metastatic urothelial carcinoma. This page synthesizes findings from peer-reviewed literature.
Research Summary
Primary indication with Phase 1/2 clinical data. In the Duravelo-1 dose-escalation study, urothelial carcinoma patients (median three prior lines of therapy) had a 38% objective response rate (8/21) and a 57% clinical benefit rate, with an 11.1 month median duration of response. Phase 2/3 Duravelo-2 registrational trial ongoing.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Zelenectide Pevedotin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.